88 related articles for article (PubMed ID: 20727867)
1. Lovastatin raises serum osteoprotegerin level in people with type 2 diabetic nephropathy.
Nezami N; Safa J; Eftekhar-Sadat AT; Salari B; Ghorashi S; Sakhaee K; Khosraviani K
Clin Biochem; 2010 Nov; 43(16-17):1294-9. PubMed ID: 20727867
[TBL] [Abstract][Full Text] [Related]
2. Effect of lovastatin therapy and withdrawal on serum uric acid level in people with type 2 diabetic nephropathy.
Nezami N; Safa J; Salari B; Ghorashi S; Khosraviani K; Davari-Farid S; Hashemi-Aghdam Y; Nargabad ON; Tabrizi JS
Nucleosides Nucleotides Nucleic Acids; 2012 Apr; 31(4):353-63. PubMed ID: 22444196
[TBL] [Abstract][Full Text] [Related]
3. Serum osteoprotegerin and tumor necrosis factor related apoptosis inducing-ligand (TRAIL) are elevated in type 2 diabetic patients with albuminuria and serum osteoprotegerin is independently associated with the severity of diabetic nephropathy.
Chang YH; Lin KD; He SR; Hsieh MC; Hsiao JY; Shin SJ
Metabolism; 2011 Aug; 60(8):1064-9. PubMed ID: 21251686
[TBL] [Abstract][Full Text] [Related]
4. Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria.
Nellemann B; Gormsen LC; Dollerup J; Schmitz O; Mogensen CE; Rasmussen LM; Nielsen S
Diabetes Care; 2007 Dec; 30(12):3122-4. PubMed ID: 17804683
[No Abstract] [Full Text] [Related]
5. Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy.
Abdin AA; Hassanien MA; Ibrahim EA; El-Noeman Sel-D
J Diabetes Complications; 2010; 24(5):325-33. PubMed ID: 19553142
[TBL] [Abstract][Full Text] [Related]
6. C-reactive protein level following treatment and withdrawal of lovastatin in diabetic nephropathy.
Rashtchizadeh N; Argani H; Ghorbanihaghjo A; Nezami N; Safa J; Montazer-Saheb S
Iran J Kidney Dis; 2009 Apr; 3(2):93-8. PubMed ID: 19395785
[TBL] [Abstract][Full Text] [Related]
7. Lovastatin for reduction of leptin in nondialysis patients with type 2 diabetic nephropathy.
Gholamin S; Razavi SM; Taghavi-Garmestani SM; Ghorbanihaghjo A; Rashtchizadeh N; Safa J; Vatankhah AM; Azizi T; Argani H
Iran J Kidney Dis; 2014 May; 8(3):201-6. PubMed ID: 24878942
[TBL] [Abstract][Full Text] [Related]
8. Plasma osteoprotegerin concentrations in type 2 diabetic patients and its association with neuropathy.
Terekeci HM; Senol MG; Top C; Sahan B; Celik S; Sayan O; Kucukardali Y; Ipcioglu O; Cagiltay E; Oktenli C; Ozata M
Exp Clin Endocrinol Diabetes; 2009 Mar; 117(3):119-23. PubMed ID: 19053023
[TBL] [Abstract][Full Text] [Related]
9. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment.
Ziolkowska M; Kurowska M; Radzikowska A; Luszczykiewicz G; Wiland P; Dziewczopolski W; Filipowicz-Sosnowska A; Pazdur J; Szechinski J; Kowalczewski J; Rell-Bakalarska M; Maslinski W
Arthritis Rheum; 2002 Jul; 46(7):1744-53. PubMed ID: 12124857
[TBL] [Abstract][Full Text] [Related]
10. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
Chiba Y; Onouchi T; Ikeda T; Adachi J; Tamura Y; Horiuchi T
Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
[TBL] [Abstract][Full Text] [Related]
11. Re: Lovastatin for reduction of leptin in nondialysis patients with type 2 diabetic nephropathy.
Ahmadi F; Mohebi-Nejad A
Iran J Kidney Dis; 2014 Jul; 8(4):344-5. PubMed ID: 25001144
[No Abstract] [Full Text] [Related]
12. Plasma osteoprotegerin concentrations in peripheral sensory neuropathy in Type 1 and Type 2 diabetic patients.
Nybo M; Poulsen MK; Grauslund J; Henriksen JE; Rasmussen LM
Diabet Med; 2010 Mar; 27(3):289-94. PubMed ID: 20536491
[TBL] [Abstract][Full Text] [Related]
13. Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women.
Kim JG; Kim JH; Lee DO; Kim H; Kim JY; Suh CS; Kim SH; Choi YM
Menopause; 2008; 15(2):357-62. PubMed ID: 17925661
[TBL] [Abstract][Full Text] [Related]
14. High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis.
Ishii R; Morimoto A; Ikushima S; Sugimoto T; Asami K; Bessho F; Kudo K; Tsunematu Y; Fujimoto J; Imashuku S
Pediatr Blood Cancer; 2006 Aug; 47(2):194-9. PubMed ID: 16358318
[TBL] [Abstract][Full Text] [Related]
15. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
Mountzios G; Dimopoulos MA; Bamias A; Papadopoulos G; Kastritis E; Syrigos K; Pavlakis G; Terpos E
Acta Oncol; 2007; 46(2):221-9. PubMed ID: 17453373
[TBL] [Abstract][Full Text] [Related]
16. [Concentration measurement of the OPG and sRANKL of peripheral blood among normal healthy people].
Zhu LL; Bao NR; Zhou LW; Guo T; Zeng XF; Zhao JN
Zhongguo Gu Shang; 2010 Feb; 23(2):87-9. PubMed ID: 20345025
[TBL] [Abstract][Full Text] [Related]
17. Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: a new link between diabetic nephropathy and cardiovascular disease?
Chico A; Pérez A; Córdoba A; Arcelús R; Carreras G; de Leiva A; González-Sastre F; Blanco-Vaca F
Diabetologia; 1998 Jun; 41(6):684-93. PubMed ID: 9662051
[TBL] [Abstract][Full Text] [Related]
18. [Changes of osteoprotegerin before and after insulin therapy in type 1 diabetic patients].
Xiang GD; Sun HL; Zhao LS; Hou J; Yue L; Xu L
Zhonghua Yi Xue Za Zhi; 2007 May; 87(18):1234-7. PubMed ID: 17686254
[TBL] [Abstract][Full Text] [Related]
19. Osteoprotegerin and RANKL serum levels and their relationship with serum ghrelin in children with chronic renal failure and on dialysis.
Ozkaya O; Buyan N; Bideci A; Gonen S; Ortac E; Fidan K; Cinaz P; Söylemezoğlu O
Nephron Clin Pract; 2007; 105(4):c153-8. PubMed ID: 17259742
[TBL] [Abstract][Full Text] [Related]
20. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin in men with thyroid cancer.
Mikosch P; Igerc I; Kudlacek S; Woloszczuk W; Gallowitsch HJ; Kresnik E; Stettner H; Grimm G; Lind P; Pietschmann P
Eur J Clin Invest; 2006 Aug; 36(8):566-73. PubMed ID: 16893379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
